Seattle startup Tasso lands $100M for self-administered blood collection devices
- ByStartupStory | December 18, 2021
Seattle based Brock, which makes equipment for the self-collection of blood samples, has received $100 million in funding. Tasso’s devices work on the upper arm, drawing blood from a network of capillaries under the skin with the push of a button. People don’t need training to collect their own blood, taking healthcare providers out of the loop and enabling applications such as remote patient monitoring.
The startup’s equipment can collect liquid or dry samples that can be sent via mail. Tasso on-demand device, which collects dry samples as dots on a strip, approved Such monitoring of patients in clinical trials, for non-clinical uses in the EU this May.
“Today, Tasso devices are successfully supporting decentralized clinical trials, clinical research, and remote patient health monitoring,” said ben casavanto, CEO and co-founder of Tasso, in a statement, Tasso also announced in October participation With InnoVero, which makes sample collection kits to test for doping in athletes using dried bloodstains.
Cassavant co-founded the company in 2011 with fellow bioengineer and CTO Irwin Berthier. The company gained in its early days grant from the Defense Advanced Research Projects Agency (DARPA), the Defense Threat Reduction Agency (DTRA), and the National Institutes of Health (NIH).
The new Series B round brings the company’s total funding so far to $131 million. The company previously raised $17 million in July 2020, on top of more than $13 million in grants. The company is also buoyed by increased interest in telehealth and at-home health care.
“With the COVID-19 pandemic, there has been a fundamental shift in how we think about healthcare, and the demand for patient-centered, in-home solutions is greater than ever,” said Casavant.
In September, researchers from the University of Washington and the Fred Hutchinson Cancer Research Center reported the results. one discovery Tasso-SST equipment for collecting liquid blood. Samples collected by COVID-19 patients themselves maintained antibody quality similar to samples collected and analyzed on-site by phlebotomists, even after being held for several days to mimic shipping times.
Follow Startup Story
Related Posts
